OCS
Live News • May 17
Oculis Shareholders Approve Expanded Share Capacity and New Director at 2026 Annual Meeting Oculis shareholders approved all agenda items at the 2026 AGM on May 13, including the election of Gregory D. Perry to the Board of Directors.
The AGM authorized a capital band increase to more than 31 million registered shares and the potential issuance of 5.75 million new treasury shares to support future offerings.
Shareholders also approved compensation limits for the Board and Executive Committee, carried forward accumulated statutory losses from 2025, and the company detailed RSU vesting, equity incentive awards, and a one-time equity grant to the new director.
These decisions point to a company setting up more funding flexibility while also formalizing its governance and compensation framework.
For you, the key questions are how and when Oculis decides to use the expanded share capacity, since any future equity offerings could affect ownership dilution and trading sentiment. Announcement • May 16
Oculis Holding Ag Announces Board and Committee Changes Oculis Holding AG announced that at the Annual General Meeting held on May 13, 2026 Gregory D. Perry was elected as a member of the Board of Directors. Lionel Carnot, Geraldine O'Keeffe and Gregory D. Perry were elected as members of the Compensation Committee. Gregory D. Perry served as Chief Financial Officer of Merus N.V. from June 2023 until January 2026, following its acquisition by Genmab in December 2025. Mr. Perry also served as audit committee chair at Merus from May 2016 to June 2023. From May 2018 until his retirement in April 2022, Mr. Perry served as the Chief Financial Officer at Finch Therapeutics Group. Mr. Perry served as the Chief Financial and Administrative Officer of Novelion Therapeutics Inc. from November 2016 to December 2017. Prior to Novelion, Mr. Perry was Chief Financial Officer of Aegerion Pharmaceuticals Inc. from July 2015 until its merger with Novelion in November 2016. He has also served as CFO of several additional biotechnology companies, and earlier in his career he held various financial leadership roles within ImmunoGen, Domantis Ltd., Transkaryotic Therapeutics, Honeywell and General Electric. Mr. Perry received a B.A. in Economics and Political Science from Amherst College. Announcement • May 09
Oculis Holding AG Announces Agreement With FDA on Special Protocol Assessment for Optic Neuritis Registrational Trial Oculis Holding AG announced that it has received written agreement from the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) regarding PIONEER-1, the first registrational trial within the PIONEER Program evaluating Privosegtor for the treatment of optic neuritis (ON). This formal FDA agreement confirms the design and planned analysis of the PIONEER-1 study are adequate to address the objectives necessary to support a future NDA submission, subject to a successful trial outcome and FDA review of the complete submission. Privosegtor is a novel peptoid small molecule that crosses the blood-brain and retinal barriers; it has the potential to become the first neuroprotective therapy for ON, with broad applicability in other neuro-ophthalmic and neurological diseases. Following the successful Phase 2 ACUITY trial, Oculis launched the PIONEER program which includes two pivotal trials to support registrational plans for Privosegtor in ON. The PIONEER-1 Phase 3 study will evaluate Privosegtor in patients with ON across a broad population, including those with and without multiple sclerosis (MS). The primary endpoint is defined as the proportion of patients achieving at least a 15-letter gain from baseline in low-contrast visual acuity (LCVA) at Month 3, a well-established endpoint for clinically meaningful visual function in ophthalmology trials. Patients will be followed for 12 months to assess Privosegtor’s long-term safety and tolerability. Dosing and patient enrollment criteria will closely mirror those of the Phase 2 ACUITY trial, in which Privosegtor + steroid showed substantial improvements in vision at Month 3, which persisted through Month 6, as measured by LCVA, along with consistent anatomical and biological neuroprotective benefits compared with placebo + steroid. The most common drug-related adverse events (AEs) were headache and acne (each in two participants; 10.5%). No drug-related serious AEs or AEs leading to treatment or study discontinuations occurred. These positive findings supported the granting of Breakthrough Therapy designation by the U.S. FDA and Priority Medicines (PRIME) designation by the European Medicines Agency (EMA) for the treatment of ON. Privosegtor, a novel peptoid small-molecule candidate that crosses the blood-brain and retinal barriers, has the potential to become the first neuroprotective therapy for optic neuritis (ON) and other neuro-ophthalmic diseases. Positive results from the ACUITY Phase 2 trial demonstrated Privosegtor’s neuroprotective potential through anatomical preservation of the retina and improvements in visual function after an acute episode of optic neuritis. Consistent results were observed in animal models of neuroinflammation and neurodegeneration, where Privosegtor preserved retinal ganglion cell damage and was associated with improvements in mobility (clinical function disability). Privosegtor has received Breakthrough Therapy designation from the FDA and Priority Medicines (PRIME) designation by the European Medicines Agency (EMA) as well as Orphan Drug from both the FDA and the EMA for ON. Privosegtor is currently being evaluated in Oculis’ PIONEER (Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research) program which includes two registrational trials in ON and one registrational trial in non-arteritic anterior ischemic optic neuropathy (NAION). In addition to its potential neuroprotective effect on the optic nerve, Privosegtor could also have wide applicability in treating other neuro-ophthalmic and neurological indications. Privosegtor is an investigational drug and has not received regulatory approval for commercial use in any country. 
